Use of Endovascular Coiling to Stop Gastric Ulcer Bleeding in a Patient With Extensive Risk Factors

Hassam Ali1, Momal Sana2, Rahul Pamarthy1

  • 1Internal Medicine, East Carolina University, Vidant Medical Center, Greenville, USA.

Cureus
|August 9, 2021
PubMed

Insights

Peptic ulcer disease can cause severe bleeding. For patients unsuitable for endoscopy, endovascular coiling is a key treatment to stop bleeding from the culprit vessel.

Area of Science:

  • Gastroenterology
  • Interventional Radiology

Background:

  • Peptic ulcer disease (PUD) is a common condition that can lead to significant gastrointestinal bleeding.
  • Endoscopy is the primary diagnostic and therapeutic tool for identifying and managing bleeding ulcers.
  • However, some patients present with bleeding ulcers that are not amenable to endoscopic intervention.

Observation:

  • This case report details a 57-year-old female experiencing melena due to a gastric ulcer.
  • The gastric ulcer was refractory to standard endoscopic treatments.
  • This necessitated alternative management strategies.

Findings:

  • Endovascular coiling, a minimally invasive embolization technique, was employed to manage the acute gastrointestinal bleeding.
  • The procedure successfully targeted and embolized the vessel supplying the gastric ulcer.
  • This highlights the efficacy of endovascular methods when endoscopy fails.

Implications:

  • Endovascular coiling offers a viable and effective alternative for managing severe peptic ulcer bleeding in patients who fail endoscopic therapy.
  • This approach can prevent life-threatening hemorrhage and reduce the need for surgical intervention.
  • Further investigation into various embolization techniques is warranted to optimize outcomes in managing ulcer bleeds.

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
182
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
190
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
512
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
720
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
840
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
629